Long-Term Givinostat Data Reinforce Safety Profile in Duchenne Muscular Dystrophy

TribeNews
0 Min Read

MedPage Today) — SAN FRANCISCO — Givinostat (Duvyzat) had a manageable long-term safety profile in Duchenne muscular dystrophy, data from an open-label extension study suggested.
Most treatment-emergent adverse events (TEAEs) were mild to…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app